MedTrace Logo

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

NCT06968312 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-16

No results posted yet for this study

Summary

This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.

Conditions

  • Post Traumatic Stress Disorder (PTSD)

Interventions

OTHER

Cognitive Processing Therapy + Hexadecanal

Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.

OTHER

Hexadecanal - Molecule Distribution in the Therapy room

Distribution of a naturally secreted molecule from body odor (Hexadecanal).

Sponsors & Collaborators

  • Weizmann Institute of Science

    collaborator OTHER

  • Tel Aviv University

    lead OTHER

Principal Investigators

  • Yair Bar Haim, PhD · Tel Aviv University

  • Noam Sobel, PhD · Weizmann Institute of Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2026-09-30
Completion
2026-12-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06968312 on ClinicalTrials.gov